Pharmafile Logo

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.

Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. 

Download and read the complimentary whitepaper at http://bit.ly/1Gmknh7  

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Emerging Markets: Your Essential Guide

Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges...

Live webinar: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,...

New appointments in our UK and New York offices

Research Partnership is delighted to announce various appointments across our offices. Ella Buckland joins as Research Executive, Ines Belchior joins as Research Analyst, and Emma Warburton joins as Business Development...

Pharma Market Research Conference NJ, 2019

We are delighted to be presenting and exhibiting at PMRC, 6-7 February in Newark, NJ.Representing Research Partnership at the conference will be New York-based Directors Liza Pliss and Mariana Servin.Liza...

Research Partnership ranks 13th in the top 20 fastest-growing agencies in the UK

The UK’s best performing market research agencies were revealed earlier this month with the publication of Research Live’s Industry Report for 2019, which includes the latest Market Research Society (MRS)...

Vaccines: Our experience and expertise

We have designed a complimentary infographic outlining the market opportunity as well as our experience and expertise in the area of vaccines. The infographic also includes links to a range of...

Conference Live: Case study

How we helped track and evaluate conference performance over time across multiple international events

Live Webinar: Poker face revealed: Using facial analysis to reveal deeper emotional insights

Thursday 28th February 2019, 10:00 EST / 15:00 GMT / 16:00 CET

Live from Singapore: Oncology in APAC – Evaluating the opportunity for novel therapies

Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST

Live webinar: Optimise your digital assets with UX research

Thursday 25th October 2018 11:00 EDT / 16:00 BST / 17:00 CEST